Key Highlights

  • The Phase 2a study of PTX-100 in cutaneous T-cell lymphoma reached its enrolment threshold for the first Dose Optimisation Committee review, with 20 evaluable patients, 10 in each arm.
  • The committee review is scheduled for December 2026, and total enrolment was 29 patients against a target of 40 evaluable patients.
  • Cash was $5.8 million at 30 September 2026, or $11.8 million pro forma including a $6.0 million raise received on 1 October.

Prescient Therapeutics (ASX:PTX), a clinical-stage oncology company, released its Appendix 4C Cash Flow Statement and Activities Report for the quarter ended 30 September 2026 on 13 October 2026.

PTX-100 Phase 2a study

On 2 September 2026 the company announced that the Phase 2a study of PTX-100 in relapsed or refractory cutaneous T-cell lymphoma (CTCL) had reached its pre-specified enrolment threshold for the first planned Dose Optimisation Committee (DOC) review. Ten evaluable patients have been enrolled in each of the two dosing arms, 20 in total, with patients evaluable after four treatment cycles. The DOC, comprising clinical and biostatistical experts, will convene in December 2026 to review safety and efficacy data and guide whether the study continues. The company stresses that this is a planned milestone in the dose optimisation design and not completion of the study.

Enrolment

Three patients were enrolled during the quarter, bringing total enrolment to 29 at 30 September 2026, up from 26 at 30 June. The company says enrolment reflected the seasonal slowdown of the Northern Hemisphere summer, where most trial sites are located. Enrolment continues towards a full target of 40 evaluable patients, with sites in Australia, the United States and Italy and work under way to open sites in France. One patient continues to receive PTX-100 on a compassionate access basis.

Capital raise

Prescient completed a Share Purchase Plan that raised $4.8 million after final reconciliation, followed by a Placement of about $1.2 million to sophisticated and professional investors, for about $6.0 million before costs. Both were priced at $0.065 per share, shares were allotted on 30 September 2026 and funds were received on 1 October 2026. The company says the proceeds will fund PTX-100 development beyond the first DOC review and into the next phase.

Financial summary

Cash was $5.8 million at quarter end, compared with $9.03 million at 30 June 2026. Net operating cash outflows were $3.2 million, including $1.98 million on Research and Development and clinical activities. Payments to related parties, being non-executive director fees, were $80,000. A new Chief Medical Officer started on 13 July 2026, and the company will hold an online investor briefing on 21 October 2026. It continues to assess further data generation for PTX-100 in peripheral T-cell lymphoma.

Dose Optimisation Committee design

The DOC will review safety and efficacy data from both dosing arms and provide guidance on whether and how the study continues, with an update to the market to follow its recommendation. Patients count as evaluable after four treatment cycles, which is why enrolment of 29 patients yields 20 evaluable patients. The company states the December review is a planned milestone and not completion of the study.

Corporate items

A new Chief Medical Officer started on 13 July 2026. The company will host an online investor briefing with its CEO on Wednesday 21 October at 11am AEDT. It says it continues to assess opportunities to generate more data for PTX-100 in peripheral T-cell lymphoma, with additional studies to be considered after the dose selection. The company's share offering, priced at $0.065, was open to existing shareholders through the SPP and to professional investors through the placement.